Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
Status:
Terminated
Trial end date:
2010-05-31
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of bosutinib administered in combination with letrozole versus
letrozole alone in post-menopausal women with breast cancer. This is a 2-part study. Subjects
in part 1 will receive bosutinib and letrozole daily, and will be closely monitored for 28
days. The second part will proceed with subjects receiving a dose that is determined to be
safe based on the safety evaluation of the first part. Eligible subjects will be randomly
assigned to receive either bosutinib daily combined with daily letrozole, or daily letrozole
alone for a specified period of time. Subjects will be followed up for survival after study
drug discontinuation.